Appointment brings deep life sciences, clinical, & global market expertise to DiaGen as it scales its AI-driven drug discovery tools and platform abroad.
VANCOUVER, BC, CANADA, March 12, 2026 /EINPresswire.com/ — DiaGen AI Inc. (“DiaGen”), a Vancouver-based AI-driven tech-bio company building proprietary tools for small molecule and peptide discovery, today announced the appointment of Aditya Tallapragada to its Advisory Board. The appointment strengthens DiaGen’s strategic advisory capabilities as the company continues to expand its AI-powered drug discovery and longevity tools and platform.
Aditya is the President of AKT Health Inc., where he leads healthcare and technology strategy for biopharma, biotech, and digital health clients across global markets. With over 15 years of experience spanning healthcare AI, clinical research, regulatory affairs, and digital transformation, he has built a career at the intersection of life sciences and emerging technology — helping organizations translate complex innovations into measurable clinical and commercial outcomes.
Throughout his career, Aditya has managed health economics and outcomes research (HEOR), KOL engagement strategies, and clinical development programs including oncology Phase II and III studies for pharmaceutical clients across East Asia and international markets. This deep foundation in clinical research and regulatory strategy gives him a unique perspective on how AI-driven tools must integrate with real-world pharmaceutical workflows to deliver practical value.
A multilingual and multicultural leader operating across the United States, Japan, the UAE, and Singapore, Aditya brings an expansive global network that spans biopharma, healthcare technology, clinical research, and investment communities. Through AKT Health, he has established strategic partnerships and convened industry leaders through initiatives such as the Decentralized Clinical Trials (DCT) Quarterly Series in Tokyo and Boston, the Global Virtual Healthcare Summit, and advisory engagements with healthcare startups and enterprises worldwide.
“What excites me most about DiaGen is the caliber of the science behind their platform and the scale of the opportunity ahead,” said Aditya. “Generative AI is fundamentally reshaping how we approach drug discovery, and DiaGen is building the tools that will define the next generation of molecular design and peptide development. I look forward to contributing to the company’s strategic growth and helping expand its reach across global healthcare and biotech markets beginning in the pacific rim and now the UAE. The potential for deeper collaboration between our teams is significant, and I’m excited about what we can build together.”
Brian D. Keane, Chairman and CEO of DiaGen AI, commented: “We are thrilled to welcome Aditya to our Advisory Board. His rare combination of hands-on clinical development experience, healthcare AI leadership, and a truly global professional network makes him exactly the kind of strategic advisor we need as DiaGen enters its next phase of growth. Aditya understands both the science and the business of healthcare innovation, and his track record of building cross-border partnerships will be invaluable as we scale our platform and expand into new markets, especially in the UAE as we will continue our efforts after previous recognition in the region
In his advisory capacity, Aditya will provide strategic counsel on healthcare AI market development, partnership origination, capital strategy, and global expansion — drawing on his extensive experience working with pharmaceutical companies, clinical research organizations, healthcare technology startups, and institutional investors across four continents.
Finally, the DiaGen board of directors reports the departure of Alexandra (“Ali”) Urman from their advisory board.
For more information, please reach out to us at IR@diagen.ai or info@akthealth.com
Or, please visit www.diagen.ai and www.akthealth.com
Contact:
Brian D. Keane
Chairman and CEO
Email: Brian@diagen.ai
About DiaGen AI Inc.
Headquartered in Vancouver, DiaGen AI Inc. is developing a diverse pipeline of AI-powered tools for small molecule and peptide discovery, diagnostics, and delivery. Using its proprietary generative AI engine, DiaGen aims to de-risk, accelerate, and create value across the global traditional drug discovery sector, advancing precision medicine and impacting global human longevity. DiaGen’s research has been accepted at NeurIPS, the premier machine learning conference, and the company is a graduate of the Creative Destruction Lab at the University of Washington. For more information, visit www.diagen.ai.
About AKT Health Inc.
AKT Health Inc. is a healthcare and technology firm that helps biopharma companies accelerate data-driven digital transformation across clinical, commercial, and medical operations. With strategic hubs in the United States, UAE, Japan, and Singapore, AKT Health combines deep domain expertise in life sciences, AI, and blockchain technology to deliver innovative solutions for the global healthcare ecosystem. For more information, visit www.akthealth.com.
Forward-Looking Statement Cautions
This press release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to the Company’s plans and expectations. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates, ” “believes,” “intends, ” “estimates,” “projects,” “aims,” “suggests,” “indicate,” “often,” “target,” “future,” “likely,” “pending,” “potential,” “goal,” “objective, ” “prospective, ” and “possibly,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. Forward-looking statements in this news release include statements relating to: the Company’s ability to make advancements in industry using its proprietary DIA technology; the Company’s focus on the AI sector; the Company providing a return on investment for its shareholders; and the continued growth of the Company, viability of its DIA technology; general applicability of AI technology towards the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; the ability of the Company to complete an intended go-public transaction; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to make advancements in industry using its proprietary DIA technology; the Company’s expectation of growth of the AI sector as it applies to healthcare; the Company’s ability to provide a return on investment for its shareholders; the continued growth of the Company; the viability of the Company’s DIA technology; the continued applicability of AI technology within the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; the ability of the Company to successfully complete a go-public transaction in the near future; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Brian Keane
Diagen AIInc.
+1 201-736-3560
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
%20(3).jpg)
